Two points i found interesting: - of the three compounds currently in clinical trials, they’re all relatively similar to known drug compounds, but unnumbered b

Two points i found interesting: - of the three compounds currently in clinical trials, they’re all relatively similar to known drug compounds, but unnumbered by patents (and hopefully more effective) - the grand challenge in drug design involves a different objective function than most are currently solving — the real challenge is to identify which protein to target, but most drug discovery assumes a known target and optimizes drug compounds for that target